Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer


Akoya Biosciences (Akoya), a Telegraph Hill Partners (THP) company, has acquired PerkinElmer, Inc.s Phenoptics„¢ portfolio. Akoya was founded in 2015 to commercialize the CODEX multiparameter tissue analysis technology developed in the lab of Dr. Garry Nolan at Stanford University. PerkinElmer has grown its Phenoptics business, to be an industry leader in multiplex immunofluorescence. This acquisition establishes Akoya as a leading provider of quantitative tissue biomarker evaluation, from discovery through translational and clinical research.

High-parameter analysis of biological tissue samples provides critical spatial context in studies of autoimmune disease, immune-oncology and many other research areas. The Phenoptics portfolio, with its Mantra, Vectra and Vectra Polaris systems, provides the throughput and standardization required to support large-scale translational studies. Its multispectral imaging instruments, reagents, software and research services have been adopted by hundreds of labs globally. CODEX enables biomarker discovery with detection of up to 50 markers on a single tissue section with reagents and instrumentation that integrate with our customers existing microscopes. CODEX includes optimized assay reagents combined with validated antibodies labeled with proprietary CODEX Barcodes to enable a simple, automated workflow.

Concurrent with the acquisition, PerkinElmers Phenoptics teams management, R&D, sales and support staff have joined Akoya. Akoya will continue to operate this team out of the greater Boston area and maintain headquarters in Menlo Park, CA. Brian McKelligon will remain as Chief Executive Officer of Akoya and Terry Lo, General Manager of the Phenoptics team at PerkinElmer, will join Akoya as President.

With both the Phenoptics portfolio and CODEX, Akoya will provide our customers with a full suite of end-to-end solutions for high parameter tissue analysis, said Brian McKelligon, CEO of Akoya. We now have the team and technologies to develop and deliver transformational solutions in the rapidly advancing field of tissue imaging.

The PerkinElmer Phenoptics team created a powerful solution already deployed at leading academic and biopharmaceutical companies with a focus on immuno-oncology, said Terry Lo, President of Akoya. We are excited to now join Akoya and catalyze further development of the Phenoptics platform as a leading technology for tissue analysis.

Telegraph Hill Partners has provided Akoya with additional funding to support further growth of the organization and continue technology and product development. By having one company with the capabilities of Phenoptics and CODEX, both PerkinElmer and THP saw the opportunity to establish the most advanced and complete solution for multiplexed tissue analysis, said Robert Shepler, Managing Director of THP. PerkinElmer was excellent throughout the process, and we look forward to further collaborations with them.

Akoya will be showcasing the latest developments from CODEX (booth #208) and the Phenoptics solutions (booth #523) at the SITC annual meeting in Washington, DC. on November 7-11. Akoya will be hosting an evening symposium featuring Dr. David Rimm, Yale University and Dr. Julia Kennedy-Darling, Akoya Biosciences.

Akoya Dinner Symposium: Innovations in high parameter spatial analysis to study the tumor microenvironment



Thursday, November 8th, 7:00 to 8:30 pm


Measuring and Multiplexing for in situ Diagnostic Tests

Dr. David Rimm, MD, Ph.D.

Professor of Pathology

Yale University School of Medicine


CODEX: Highly Multiplexed Tissue Profiling for Single Cell Spatial Analysis

Dr. Julia Kennedy-Darling, Ph.D.

Director of R&D

Akoya Biosciences


To register for the event, visit us at:

About Akoya Biosciences

Akoya Biosciences develops innovative technologies for life science researchers to enable spatially-resolved, quantitative tissue phenotyping at the cellular and subcellular level. The combined technologies of Phenoptics and CODEX are fueling advances in next generation tissue analysis by providing comprehensive solutions including instrumentation, reagents and software. Akoya Biosciences is headquartered in Menlo Park, CA.

For more information, please visit

Akoya Biosciences
Chris Streck

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.